875272-89-2

Usage

Uses

Used in Pharmaceutical Industry:
(S)-4-fluoro-4-Methyl-2-((S)-2,2,2-trifluoro-1-(4'-(Methylsulfonyl)biphenyl-4-yl)ethylaMino)pentanoic acid is used as a precursor or building block for the synthesis of new pharmaceutical compounds due to its unique structural features and the potential for specific interactions with biological targets.
Used in Drug Development:
(S)-4-fluoro-4-Methyl-2-((S)-2,2,2-trifluoro-1-(4'-(Methylsulfonyl)biphenyl-4-yl)ethylaMino)pentanoic acid is utilized in drug development for the creation of novel therapeutic agents, potentially targeting a range of diseases and conditions. Its complex structure allows for the possibility of fine-tuning its properties to achieve desired pharmacological effects.
Used in Medicinal Chemistry Research:
(S)-4-fluoro-4-Methyl-2-((S)-2,2,2-trifluoro-1-(4'-(Methylsulfonyl)biphenyl-4-yl)ethylaMino)pentanoic acid serves as a subject of study in medicinal chemistry research, where its properties and interactions with biological systems are explored to understand its potential as a therapeutic agent or as a tool for probing biological mechanisms.

Upstream product

• 893407-18-6 2,2,2-trifluoro-1-(4‘-(methylsulfonyl)-[1,1'-biphenyl]-4-yl)ethanone 
• 25895-60-7 sodium cyanoborohydride 
• 848949-85-9 ethyl (2S)-2-amino-4-fluoro-4-methylpentanoate sulfate salt 
• 92-86-4 4-(4-bromophenyl)bromobenzene 
• 16184-89-7 4'-bromo-2,2,2-trifluoroacetophenone 
• 3393-00-8 (4’-bromo-[1,1’-biphenyl]-4-yl)(methyl)sulfane 
• 1004294-77-2 2,2,2-trifluoro-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethan-1-one 
• 2095926-24-0 (S)-ethyl 2-amino-4-fluoro-4-methylpentanoate hydrochloride 
• 893407-15-3 2,2,2-trifluoro-1-(4‘-(methylthio)-[1,1‘-biphenyl]-4-yl)ethanone 
• 589-87-7 1,4-bromoiodobenzene 
• 98546-51-1 (4-thiomethoxyphenyl)boronic acid 

Downstream Products

• 1064076-86-3 (2S)-4-fluoro-4-methyl-2-({(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}amino)pentanoic acid dicyclohexylamine salt 

Relevant academic research and scientific papers

CATHEPSIN INHIBITORS

This invention relates to compounds that are useful as inhibitors, in particular as inhibitors of Cathepsin K (CatK), and to a method of inhibiting cathepsin activity, comprising administering a compound or formulation comprising a compound according to the invention.

The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K

Irreversible covalent inhibitors can have a beneficial pharmacokinetic/pharmacodynamics profile but are still often avoided due to the risk of indiscriminate covalent reactivity and the resulting adverse effects. To overcome this potential liability, we introduced an alkyne moiety as a latent electrophile into small molecule inhibitors of cathepsin K (CatK). Alkyne-based inhibitors do not show indiscriminate thiol reactivity but potently inhibit CatK protease activity by formation of an irreversible covalent bond with the catalytic cysteine residue, confirmed by crystal structure analysis. The rate of covalent bond formation (kinact) does not correlate with electrophilicity of the alkyne moiety, indicative of a proximity-driven reactivity. Inhibition of CatK-mediated bone resorption is validated in human osteoclasts. Together, this work illustrates the potential of alkynes as latent electrophiles in small molecule inhibitors, enabling the development of irreversible covalent inhibitors with an improved safety profile.

Preparation method of odanacatib, and preparation method of odanacatib intermediate

The invention discloses a preparation method of odanacatib, and a preparation method of an odanacatib intermediate. The preparation method of the trifluoroethylketone biphenyl methylsulfone intermediate I comprises the following step: 2,2,2-trifluoro-1-[4

A practical enantioselective synthesis of odanacatib, a potent cathepsin K inhibitor, via triflate displacement of an α-Trifluoromethylbenzyl triflate

An enantioselective synthesis of the Cathepsin K inhibitor odanacatib (MK-0822) 1 is described. The key step involves the novel stereospecific S N2 triflate displacement of a chiral α-trifluoromethylbenzyl triflate 9a with (S)-γ-fluoroleucine e

Diastereoselective reductive amination process

This invention describes a reductive amination process whereby perfluorinated ketones or ketals are combined with α-aminoesters under basic conditions to form metal carboxylates. Diastereoselective reductions of the metal carboxylates enable access to two